Navigation Links
Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board
Date:5/20/2013

San Diego, CA (PRWEB) May 20, 2013

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Robert L. Wilensky, MD, Professor of Medicine and Director of Interventional Cardiology Research at the University of Pennsylvania has agreed to join the Scientific and Medical Advisory Board for Stemedica’s Cardiology Division.

At the University of Pennsylvania, Dr. Wilensky divides his time between the cardiac catheterization laboratories and the translational animal laboratory. His research interests include acute coronary syndromes, diagnosis and treatment of vulnerable coronary lesions and stem cell therapy for decreased left ventricular function and coronary artery disease.

Stephen Epstein, MD, Chairman of Stemedica’s Cardiology Division Scientific and Medical Advisory Board commented, “Dr. Wilensky’s strong interest and expertise in both interventional cardiology and translational medicine, most notably with stem cells, parallels and strongly supports the direction we are taking with Stemedica.”

Dr. Wilensky received his MD degree with distinction from the University of Amsterdam. His internship and residency in Internal Medicine was obtained at the Georgetown University Medical Center in Washington, DC. His fellowship in Cardiology was at the Krannert Institute of Cardiology, Indiana University, where he was Chief Fellow and later Assistant Professor of Medicine. He joined the faculty of the University of Pennsylvania in 1996.

Dr. Wilensky has been an active organizer of, and participant in, many international cardiology symposia, including the Cardiovascular Revascularization Therapies meetings and Transcatheter Therapeutics Meetings. He has lectured both domestically and internationally. He is a Fellow of the American College of Cardiology and the American Heart Association. He is the author or co-author of over 165 papers and has been issued three US patents. His pioneer work on comparing different methods of stem cell delivery in acute myocardial infarction pig model has made a significant contribution to the understanding of the mechanism of action of mesenchymal stem cells.

Sergey Sikora, PhD, President of Stemedica’s Cardiovascular Division noted, “As we explore the best delivery systems for cardiac stem cell treatment, we will draw upon Dr. Wilensky’s experience in this key area. He will be an invaluable contributor in the planning of future pre-clinical and clinical studies in the area of acute myocardial infarction.”

Maynard Howe, Ph.D., Chief Executive Officer, and Vice Chairman of Stemedica commented, “We are delighted to have another world-class cardiac clinician and researcher join our team. We look forward to working with Dr. Wilensky.”

Stemedica currently has three FDA-approved clinical trials underway in ischemic stroke, acute myocardial infarct and cutaneous photoaging.

About Stemedica Cell Technologies, Inc. http://www.stemedica.com
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc., contact Dave McGuigan at dmcguigan(at)stemedica(dot)com.

Read the full story at http://www.prweb.com/releases/stemedica-stem-cells/cardiology-r-wilensky/prweb10749049.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Steady Rise in Heart Valve Infections Noted in U.S.
2. Diminished Taste Buds Noted in Obese Children
3. Beaumont Cardiologist Kavitha Chinnaiyan, M.D., Receives Excellence in Research Award
4. Beaumont cardiologist Kavitha Chinnaiyan, M.D., receives excellence in research award
5. Pets a Boon for the Human Heart, Cardiologists Say
6. Pediatric cardiologist at CHOP receives major teaching award at ACC National Conference
7. HeartView Global Foundation honors World-Renowned Cardiologist, Asher Kimchi and Philanthropist Diane Brinson
8. HF patients treated by a cardiologist, rather than hospitalist, have fewer readmissions
9. Pittsburgh Cardiologist Named Physician of the Year by Pulmonary Hypertension Association
10. The Biology of Cancer by Robert A. Weinberg
11. Robert Korwin DMD, and Susan Korwin Life Coach and Author, Present to Students at West New York Middle School Career Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: